Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC eyes J&J-Pfizer

This article was originally published in The Tan Sheet

Executive Summary

The European Commission says it will decide by Nov. 27 whether to sign off on Johnson & Johnson's proposed acquisition of Pfizer Consumer Healthcare or to open a full-scale investigation in a process that could last three months. The EC's Competition Directorate will accept comments on the proposed deal until 10 calendar days from the date it announced its preliminary review, Oct. 26. J&J proposes paying $16.6 bil. for Pfizer's OTC brands, including Nicorette and Sudafed (1"The Tan Sheet" July 3, 2006, p. 3). To facilitate the deal's completion, J&J already has agreed to sell its OTC Zantac heartburn medication to Boehringer for $509 mil. (2"The Tan Sheet" Oct. 16, 2006, p. 9)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS099893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel